Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
WtD0PPVTg1gqTQfc
Listen
